Company news

C4 Therapeutics, Inc. news in 2026

C4 Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

C4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights

November 5, 2026

C4 Therapeutics to Participate in Upcoming November Investor Conferences

November 3, 2026

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

November 2, 2026

C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders

October 29, 2026

C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting

September 25, 2026

C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed, Refractory Multiple Myeloma Trial

September 4, 2026

C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting

September 3, 2026

C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

August 11, 2026

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

June 10, 2026

C4 Therapeutics to Participate in Upcoming Conferences

May 20, 2026

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 12, 2026

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

April 8, 2026

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

March 24, 2026

C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

February 25, 2026

C4 Therapeutics to Participate in Upcoming March Conferences

February 23, 2026

C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma

February 22, 2026

C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

February 4, 2026

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 26, 2026

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

January 14, 2026

Decks in 2026